The patient received a combination of ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) complicated by hypothyroidism and elevated liver enzymes after his second dose, which was treated by levothyroxine and prednisone, followed by mycophenolate mofetil, respectively. This evidence concerns the gene CTLA4 and hypothyroidism.